In his weekly clinical update, Dr. Griffin discusses progress toward measles elimination, risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune-suppressive drugs, symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals, late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial, higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19, recombinant C1 inhibitor in the prevention of severe COVID-19, and Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course.
In his weekly clinical update, Dr. Griffin discusses coverage with selected vaccines and exemption from school vaccine requirements among children in kindergarten, seasonality of endemic COVID-19, mRNA SARS-CoV-2 vaccination before vs during pregnancy and omicron infection among infants, extracting symptoms from free-text responses using ChatGPT among COVID-19 cases in Hong Kong, SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy, optimization of antiviral therapy in immunocompromised COVID-19 patients, a study to learn about the study medicines (nirmatrelvir plus ritonavir) in people aged 12 years or older with COVID-19 and a compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment on early trajectories of virologic and immunologic biomarkers in patients hospitalized with COVID-19, and SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy.
In his weekly clinical update, Dr. Griffin discusses stress in America 2023, CDC expanding testing of international air traveler samples to include flu, RSV, and other respiratory viruses, missed opportunities for preventing congenital syphilis, intrinsic and effective severity of COVID-19 cases infected with the ancestral strain and omicron BA.2 variant in Hong Kong, T-cell immunity against severe acute respiratory syndrome coronavirus 2 measured by an interferon-γ release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with delta or omicron variants, masks during pandemics caused by respiratory pathogens, behavioral factors and SARS-CoV-2 transmission heterogeneity within a household cohort in Costa Rica, convalescent plasma for Covid-19–induced ARDS in mechanically ventilated patients, and olfactory and gustatory function 3 years after mild COVID-19.
In his weekly clinical update, Dr. Griffin discusses health worker–perceived working conditions and symptoms of poor mental health, Mpox neutralizing antibodies at 6 months from mpox infection or MVA-BN vaccination, newborn and early infant outcomes…
In his weekly clinical update, Dr. Griffin discusses health worker–perceived working conditions and symptoms of poor mental health, Mpox neutralizing antibodies at 6 months from mpox infection or MVA-BN vaccination, newborn and early infant outcomes following maternal COVID-19 vaccination during pregnancy, duration of SARS-CoV-2 culturable virus shedding in children, prescribing outcomes in outpatients treated with nirmatrelvir–ritonavir for COVID-19 in an interdisciplinary community clinic, Nirmatrelvir and molnupiravir and post-COVID-19 condition in older patients, optimal duration of systemic corticosteroids in COVID-19 treatment, association between Guillain-Barré syndrome and COVID-19 infection and vaccination, SARS-CoV-2 infection correlates with male benign prostatic hyperplasia deterioration, Transplanting candidates with COVID-19, and favorable experience of transplant strategy including liver grafts from COVID-19 donors.
In his weekly clinical update, Dr. Griffin discusses high Influenza incidence and disease severity among children and adolescents aged <18 years, neurologic effects of SARS-CoV-2 transmitted among dogs, effectiveness of monovalent mRNA vaccines against Omicron XBB infection in Singaporean children younger than 5 years, the effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions, incidence and impact of acute pericarditis in hospitalized patients with COVID‐19, serotonin reduction in post-acute sequelae of viral infection, prevalence and risk factors for long COVID and post-COVID-19 condition in Africa, safety profile and clinical and virological outcomes of nirmatrelvir-ritonavir treatment in patients with advanced chronic kidney disease and COVID-19, antiviral efficacy of molnupiravir vs ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19.
In his weekly clinical update, Dr. Griffin discusses disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults aged ≥60 years, antiviral efficacy of Molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to covid-19 complications, antibiotic use among hospitalized patients with COVID-19 in the United States, one week of oral Camostat vs Placebo in nonhospitalized adults with mild-to-moderate COVID-19, assessment of the available therapeutic approaches for severe COVID-19, optimal duration of systemic Corticosteroids in COVID-19 treatment, effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome, local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients, and the safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic Kidney disease and COVID-19.
In his weekly clinical update, Dr. Griffin discusses the effectiveness of maternal mRNA COVID-19 vaccination during pregnancy against COVID-19–associated hospitalizations in infants aged <6 months during SARS-CoV-2 Omicron predominance, COVID-19 vaccination recommendations and practices for women of reproductive age by health care providers, molnupiravir for intra-household prevention of COVID-19, delayed peak SARS-CoV-2 viral loads relative to symptom onset and implications for COVID-19 testing programs, viral kinetics of sequential SARS-CoV-2 infections, FDA authorizes updated Novavax COVID-19 vaccine formulated to better protect against currently circulating variants, antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, long-term cardiovascular, cerebrovascular, and other thrombotic complications in COVID-19 survivors, SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels, and the efficacy of gabapentin For post-COVID-19 olfactory dysfunction.
In his weekly clinical update, Dr. Griffin discusses a molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, inhaled fluticasone furoate for outpatient treatment of COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, early antibody treatment, inflammation, and risk of post-COVID conditions, autonomic dysregulation in long-term patients suffering from post-COVID-19 syndrome assessed by heart rate variability, and multiorgan MRI findings after hospitalization with COVID-19 in the UK.
In his weekly clinical update, Dr. Griffin discusses wastewater surveillance data as a complement to emergency department visit data for tracking the incidence of influenza A and RSV, chatbot-delivered online intervention to promote seasonal Influenza vaccination during the COVID-19 pandemic, temporal assessment of disparities in California COVID-19 mortality by industry, modeling the impact of a high-uptake bivalent booster scenario on the COVID-19 burden and healthcare costs in New York City, can high COVID-19 vaccination rates in adults help protect unvaccinated children, Nirmatrelvir/Ritonavir use and hospitalizations or death in previously uninfected non-hospitalized high-risk population with COVID-19, Optimal duration of systemic corticosteroids in COVID-19 treatment, and vaccination after developing long COVID.